
NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Impact and Inclusivity – How the NLA Does It
We celebrated the twentieth anniversary of the NLA in 2022. It seems appropriate, when considering the impact of the NLA on the healthcare community, to…
Why is this Small Adult in My Office? How to Identify, Treat, and Advocate for Children with Familial Hypercholesterolemia
Heterozygous familial hypercholesterolemia (HeFH) is an autosomal co-dominant genetic disorder, affecting roughly 1 in 220 people; characterized by lifelong elevated levels of LDL cholesterol (LDL-C)…
Dietary Supplements or Statins for LDL-C Lowering
More than half of adults in the United States report taking dietary supplements. For example, some choose supplements in place of statins in hopes of…
The Place of the Lipid Specialist in the Medical Community
A medical specialist is a provider/clinician with expertise beyond the generalist. The National Lipid Association (NLA) partners with the American Board of Clinical Lipidology (ABCL)…
To Stop the Rise in Cardiovascular Deaths, We Must Take Action outside the Clinic
As healthcare professionals, we devote our careers to service. We hope to make a lasting impact for each of our patients. Our advancements in treating…
The ABCs of Lipoprotein(a)
In recent years, lipoprotein(a) [Lp(a)] has been recognized as a prevalent risk factor for cardiovascular disease. It is estimated that ~20% of the global population…
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology
Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the…
Aspirin Use and Lipoprotein(a) Genotypes in Primary Prevention
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Although approximately 20% of the population has elevated Lp(a) levels (≥ 50 mg/dL…